CXCL13/BLC/BCA-1 Antibody (53602) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # FAB8012C
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Intracellular Staining by Flow Cytometry, Neutralization
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # 53602
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
E. coli-derived recombinant human CXCL13/BLC/BCA-1
Val23-Arg94
Accession # O43927
Val23-Arg94
Accession # O43927
Specificity
Detects human CXCL13/BLC/BCA-1 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for CXCL13/BLC/BCA-1 Antibody (53602) [PerCP]
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Intracellular Staining by Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Neutralization
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CXCL13/BLC/BCA-1
Alternate Names
ANGIE2, BCA-1, BCA1, BLC, BLR1L, SCYB13
Additional CXCL13/BLC/BCA-1 Products
Product Documents for CXCL13/BLC/BCA-1 Antibody (53602) [PerCP]
Product Specific Notices for CXCL13/BLC/BCA-1 Antibody (53602) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...